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1  | INTRODUC TION
Coagulation tests are widely used in healthcare for the screen-
ing, diagnosis, and assessment of coagulopathies, the monitoring 
of anticoagulant therapy, and as a component of preoperative 
screening.1-3 Fibrinogen levels, thrombin time and D- dimer levels 
are frequently measured in clinical practice; it is important that 
tests for these analytes are accurate and reliable, and that re-
sults are available in a timely manner. Fibrinogen levels are mea-
sured to determine haemorrhagic or thrombotic status. Elevated 
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Abstract
Introduction: New laboratory methods to measure haemostatic function require 
careful assessment before routine use. We evaluated the analytical performance of 
four new coagulation assays for the measurement of fibrinogen by Clauss assay, pro-
thrombin time- derived fibrinogen, thrombin time and D- dimer levels.
Methods: The four assays were evaluated on the cobas t 711 and cobas t 511 analys-
ers	at	four	centres	in	Europe.	Analytical	performance	and	method	comparisons	with	
other commercially available assays were performed according to Clinical and 
Laboratory	 Standards	 Institute	 guidelines	 (EP09-	A3,	 EP05-	A3)	 using	 residual	 an-
onymized	human	sodium	citrate	(3.2%	[0.109M])	plasma	samples.	Lot-	to-	lot	variabil-
ity and the equivalency of each assay on the cobas t 711 and cobas t 511 analysers 
were also assessed.
Results:	Overall,	coefficients	of	variance	were	≤4.1%	and	≤8.6%	for	within-	run	preci-
sion	and	total	reproducibility,	respectively.	Method	comparison	experiments	showed	
good or acceptable agreement for each assay compared with their respective com-
parator method, and equivalency was demonstrated for the two cobas t platforms 
(Pearson’s	correlation	coefficient	≥0.991).	A	high	level	of	consistency	was	observed	
between	lots	for	all	four	assays	(Pearson’s	correlation	coefficient	≥0.994).
Conclusion:	This	multicentre	study	demonstrates	excellent	analytical	performance	
for four new coagulation assays on the cobas t 711 and cobas t 511 analysers.
K E Y W O R D S
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levels of fibrinogen are a risk factor for thrombotic disease and 
have been observed during acute- phase reactions, pregnancy, 
oral contraception use, menopause, malignancies, chronic in-
flammatory diseases and in people who smoke.1,4-9 Low fibrin-
ogen levels can occur during acute or chronic liver disease, 
disseminated intravascular coagulation (DIC), thrombolytic ther-
apy, haemodilution and consumption coagulopathy.9-11 Thrombin 
time tests can be used to investigate possible bleeding disor-
ders or the occurrence of thrombotic episodes. Thrombin time 
is prolonged by: decreased fibrinogen levels; abnormal function 
of fibrinogen; the presence of direct thrombin inhibitors, such 
as dabigatran, bivalirudin or argatroban; the presence of unfrac-
tionated heparin; the presence of aprotinin; and the presence of 
fibrinogen/fibrin degradation products and/or increased fibrino-
lysis	 (for	example,	due	to	thrombolytic	therapy).12-17 D- dimer is 
a very sensitive marker for the activation of coagulation.18-24 In 
DIC, fibrin degradation products, such as D- dimer, can be used 
to confirm or refute a tentative diagnosis, estimate the potential 
risk	for	patients	with	existing	DIC,	and	monitor	an	initiated	ther-
apy.25-27	D-	dimer	 levels	 are	particularly	useful	 to	exclude	deep	
vein	 thrombosis	 (DVT)	 and	 pulmonary	 embolism	 (PE),	 and	may	
be elevated in the presence of other causes of fibrin formation 
such as trauma, pregnancy complications, malignant disease or 
vascular abnormalities.25-30
High- throughput technologies designed for use in core labora-
tories and developed to measure fibrinogen, prothrombin time (PT)- 
derived fibrinogen, thrombin time and D- dimer may offer significant 
benefits, such as reduced error rates and increased efficiency. This 
multicentre study aimed to evaluate the performance of four new 
coagulation assays on the cobas t 711 and cobas t 511 analysers, 
which have been developed to measure fibrinogen, among others, 
PT- derived fibrinogen, thrombin time and D- dimer levels. For each 
assay, the analytical performance was evaluated and method com-
parisons	with	existing	commercially	available	assays/platforms	were	
performed.
2  | MATERIAL S AND METHODS
2.1 | Study design
This	 study	 was	 performed	 between	 June	 2016	 and	 March	 2017	
in	 core	 laboratories	 at	 four	 centres	 in	 Europe	 (Medical	 University	
of	 Vienna,	 Vienna,	 Austria;	 University	 Medical	 Center	 Freiburg,	
Freiburg, Germany; University of Debrecen, Debrecen, Hungary; 
Royal Hallamshire Hospital, Sheffield, UK). The four assays pre-
sented here (fibrinogen, PT- derived fibrinogen, thrombin time and 
D-	dimer;	 Roche	 Diagnostics	 GmbH,	 Mannheim,	 Germany)	 were	
each evaluated for their analytical performance, and compared with 
existing	methodologies/technologies	 in	 independent	method	 com-
parison	 experiments.	 Lot-	to-	lot	 variability	 and	 the	 equivalency	 of	
each assay on two cobas t platforms (cobas t 711 and cobas t 511; 
Roche	Diagnostics)	were	also	assessed.	All	assays	and	 instruments	
were used according to their respective manufacturers’ instructions 
and quality control measurements were performed at least twice 
daily.	 Residual	 anonymized	 human	 sodium	 citrate	 (3.2%	 [0.109M])	
plasma	samples	from	clinics’	routine	were	used	for	all	experiments.	
Independent ethics committee approval or waiver was obtained be-
fore study initiation where required, and the study was performed 
according to the principles of the Declaration of Helsinki and the 
International Council for Harmonisation of Technical Requirements 
for Pharmaceuticals for Human Use Good Clinical Practice guidelines.
2.2 | Experimental procedures and data analysis
Each of the four assays was independently evaluated on the cobas t 711 
analyser (high- throughput: 390 tests/h; evaluated at all four sites) and 
cobas t 511 analyser (mid- throughput: 195 tests/h; evaluated at two 
sites	[UK;	Germany]).	Within-	run	precision	for	each	assay	was	evaluated	
in one run using two controls and five human plasma samples (n = 21 
replicates	per	sample);	each	site	performed	their	experiments	with	an	
individual reagent and control lot, which varied by site. Reproducibility 
TABLE  1 Within- run precision and total reproducibility (across all four sites) of the four coagulation assays on the cobas t 711 and cobas t 
511 analysers
Assay
Within- run precision 
acceptance criteria
Within- run precision, range of % 
CV or SD Total reproducibility 
acceptance criteria  
(%)
Total reproducibility, range 
of % CV
cobas t 711 cobas t 511 cobas t 711 cobas t 511
Fibrinogen (mg/dL) CV	≤	4.0%	(60-	400) 0.8- 2.3 0.8- 1.5 CV	≤	25.0 2.1- 3.0 1.6- 2.6
CV	≤	6.0%	(400-	600) 0.7- 2.6 0.7- 0.9 CV	≤	25.0 3.3 2.9
CV	≤	10.0%	(>600) 1.8- 2.6 0.6- 1.4 CV	≤	25.0 4.3 4.3
PT- derived fibrinogen 
(mg/dL)
CV	≤	5.0% 0.4- 1.4 0.4- 1.3 CV	≤	25.0 1.4- 2.2 1.1- 3.1
Thrombin time (s) CV	≤	4.0% 0.6- 2.9 0.6- 4.1 CV	≤	25.0 1.1- 4.5 0.9- 4.0
D- dimer (μg FEU/mL) SD	≤	0.02	(<0.56) 0.012- 0.017 0.0096- 0.016 CV	≤	25.0 3.5- 8.6 3.3- 6.7
CV	≤	3.5%	(0.56-	1.7) 1.5- 2.4 1.4- 1.5 CV	≤	25.0 5.4 5.5
CV	≤	3.0%	(>1.7) 0.3- 0.7 0.2- 0.3 CV	≤	25.0 1.0- 1.8 0.9- 2.2
CV,	coefficient	of	variation;	FEU,	fibrinogen	equivalent	units;	PT,	prothrombin	time;	SD,	standard	deviation.
Ranges reported are for human plasma samples only, covering a concentration range of 70- 800 mg/dL.
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was evaluated over 5 days by measuring five aliquots of each control 
sample and of five human plasma samples, using the same control lots 
and reagent lots at all sites. Results were evaluated across the study sites.
Briefly, the fibrinogen test is a Clauss assay using lyophilized bo-
vine thrombin at a concentration of 100 National Institutes of Health 
(NIH) units/mL with added stabilizers and buffers; the PT- derived fi-
brinogen assay is a Quick test containing recombinant thromboplas-
tin	and	calcium	to	activate	the	extrinsic	coagulation	cascade	when	
added to citrated human plasma; and the thrombin test is based on 
a lyophilized reagent containing 2000- 10 000 NIH units/L of bovine 
thrombin	per	supplied	vial,	which	was	mixed	with	the	sample	in	a	1:1	
ratio. The D- dimer test is a particle- enhanced immunoturbidometric 
assay	in	which	latex	particles	are	coated	with	monoclonal	antihuman	
D- dimer antibodies (mouse) at 0.12%. The start reagent is used to-
gether with a preservative/buffer solution at pH 8.2.
The full study methods, including evaluation of analytical per-
formance, equivalency of the cobas t 711 and cobas t 511 analysers, 
lot- to- lot comparison, reference range evaluation, and data analy-
sis have been described previously (for the evaluation of five other 
coagulation tests on the cobas t 711 and cobas t 511 analysers).31
2.3 | Method comparison
A	method	comparison	was	performed	for	each	assay	(using	the	cobas 
t 711 analyser) vs the following respective comparator methods, 
according	to	Clinical	and	Laboratory	Standards	Institute	(CLSI)	EP09-	A3	
guidelines:32	fibrinogen	vs	Dade	Thrombin	Reagent	on	Siemens	Sysmex	
CS- 5100 or CS- 2000i; PT- derived fibrinogen (lyophilized, recombinant 
human thromboplastin reagent containing a heparin- neutralizing sub-
stance, calcium chloride, stabilizers, and buffers; this method has been 
standardized against the fibrinogen method available on cobas t co-
agulation analysers and is thus traceable to the international standard 
WHO 09/264) vs Fibrinogen (Clauss) on cobas t 711; thrombin time vs 
BC Thrombin on Siemens BCS; D- dimer vs Tina- quant® D- Dimer Gen 
2 reagent on Roche/Hitachi cobas c systems (cobas c 502, cobas c 701, 
or cobas c 501). Each comparison was performed at three or four sites 
(two reagent lots per site) using a minimum of 120 residual anonymized 
human plasma samples per assay (representing the appropriate meas-
uring range of the relevant analyte).
2.4 | Reference range studies
For all assays, reference ranges were determined using anonymized re-
sidual	samples	(0.109M/3.2%	citrate)	sourced	from	apparently	healthy	
adult donors at a blood bank (Freiburg, Germany). Key inclusion criteria 
were: 18- 50 years of age, originating from Europe or the US and able to 
provide	written	informed	consent;	exclusion	criteria	were	self-	declared	
pregnancy or breast- feeding, and use of anticoagulation medication in-
cluding but not limited to acetyl salicylic acid, direct oral anticoagulants, 
phenprocoumon, and warfarin. Samples were collected in Sarstedt 
TABLE  2 Method	comparison:	cobas t 711 vs comparator device
Comparison Evaluation Acceptance criteria
Freiburg Sheffield Debrecen
Lot 1 Lot 2 Lot 3
Fibrinogen vs Dade Thrombin 
Reagent
n 140 155 130
Slope (Deming) 1.00 ± 0.10 0.985 0.959 0.977
Intercept ≤25.0	mg/dL 10.506 16.489 11.605
Pearson’s r ≥0.900 0.996 0.991 0.990
Relative % bias at 200 mg/dL NA 3.78 4.10 3.48
PT- derived fibrinogen vs 
Fibrinogen (Clauss)
n 144 126 128
Slope (Passing- Bablok) 1.00 ± 0.15 1.000 0.955 1.067
Intercept NA 14.500 16.227 −6.467
Pearson’s r ≥0.850 0.943 0.938 0.940
Bias at 200 mg/dL ±20 mg/dL at 200 mg/dL 14.50 7.14 6.87
Thrombin time vs BC Thrombin 
Reagent
n 137 146 122
Slope (Deming) 1.00 ± 0.35 0.670 0.868 0.960
Intercept NA 7.425 5.353 3.089
Pearson’s r ≥0.70 0.751 0.755 0.658
Relative % bias at 17.8 s NA 8.68 16.8 13.3
D- dimer vs Tina- quant® 
D- dimer
n 216 194 134
Slope (Deming) 1.000 ± 0.100 1.006 0.995 1.033
Intercept ≤±0.20	μg FEU/mL 0.004 −0.041 −0.012
Pearson’s r ≥0.950 1.000 0.999 0.999
Relative % bias at 0.5 μg FEU/mL NA 1.48 8.61 0.997
FEU,	fibrinogen	equivalent	units;	NA,	not	applicable;	PT,	prothrombin	time.
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tubes, and as reported previously, samples were measured fresh at the 
sampling	site	in	Freiburg.	All	experiments	were	performed	using	three	
reagent lots (N = 200; n = 66 or 67 samples per lot). Reference ranges 
for	each	assay	were	also	derived	 from	frozen	0.109M/3.2%	citrated	
samples	(BIOMEX	GmbH,	Heidelberg,	Germany)	purchased	in	Becton	
Dickinson	tubes	(San	Jose,	CA,	USA),	and	in	frozen	aliquots	of	the	an-
onymized residual samples from apparently healthy adult donors, col-
lected in Sarstedt tubes. Both types of frozen samples were measured 
at three different sites after thawing (one reagent lot per site). Ranges 
were quoted as 2.5th- 97.5th percentiles with 90% confidence intervals 
(CI) and were accompanied by median values.
3  | RESULTS
3.1 | Analytical performance
For	each	assay,	the	coefficients	of	variation	(CVs)	for	within-	run	preci-
sion and total reproducibility are presented in Table 1; all values were 
within	the	prespecified	acceptance	criteria.	Across	all	four	sites	and	
all	 four	 assays,	CVs	 for	within-	run	precision	 in	human	plasma	 sam-
ples ranged from 0.3% to 2.9% on the cobas t 711 analyser and from 
0.2% to 4.1% on the cobas t	511	analyser.	CVs	for	total	reproducibility	
across all four sites and all four assays ranged from 1.0% to 8.6% on 
F IGURE  1 Method	Comparison	Between	(A)	Fibrinogen	on	cobas t	711	vs	Dade	Thrombin	Reagent	on	Siemens	Sysmex	CS-	5100	
(Freiburg), (B) PT- Derived Fibrinogen on cobas t 711 vs Fibrinogen (Clauss) on cobas t 711 (Sheffield), (C) Thrombin time on cobas t 711 
vs BC Thrombin on Siemens BCS (Debrecen), and (D) D- dimer on cobas t 711 vs Tina- Quant® D- dimer Gen 2 Reagent on Roche/Hitachi 
cobas c	701	(Sheffield).	Representative	examples	from	each	site	shown
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the cobas t 711 analyser and from 0.9% to 6.7% on the cobas t 511 
analyser.
3.2 | Method comparison
The fibrinogen, PT- derived fibrinogen, and D- dimer assays showed 
good agreement vs their respective comparator methods according 
to prespecified criteria (specified in Product Specifications Document) 
based on Deming or Passing–Bablok regression analyses (Table 2; 
Figure 1). Pearson’s correlation coefficients (presented as a range 
across three sites) were as follows: fibrinogen (cobas t 711) vs Dade 
Thrombin	Reagent	on	Siemens	Sysmex	CS-	5100/CS-	2000i,	r = 0.990- 
0.996; PT- derived fibrinogen (cobas t 711) vs Fibrinogen (Clauss) on 
cobas t 711, r = 0.938- 0.943; thrombin time (cobas t 711) vs Siemens 
BC Thrombin on Siemens BCS, r = 0.658- 0.755; D- dimer (cobas t 711) 
vs Tina- quant® D- Dimer Gen 2 reagent on Roche/Hitachi cobas c 
systems, r = 0.999- 1.000. Relative bias within the data for each assay 
shows some variation between sites (Figures S1-S4).
3.3 | Equivalency of cobas t 711 and cobas t 
511 analysers
For each of the four assays evaluated, the cobas t 711 and cobas t 
511 platforms demonstrated equivalence, according to prespecified 
acceptance criteria based on Passing–Bablok regression analy-
ses	 (Table	3).	Across	all	 four	assays	and	sites	 (two	sites	per	assay),	
Pearson’s	 correlation	 coefficient	 exceeded	 acceptance	 criteria.	
Bland-	Altman	 plots	 (Figures	S5-S8)	 demonstrate	 constant	 bias	 for	
the four assays and consistency in results for each site.
3.4 | Lot- to- lot comparison
A	high	level	of	consistency	between	lots	was	observed	for	all	four	as-
says on the cobas t 711 analyser (Table 4); the prespecified equiva-
lence criteria based on Passing–Bablok analyses were met. For all 
four assays and comparisons (Lot 2 vs 1, Lot 3 vs 2, and Lot 1 vs 
3),	Pearson’s	correlation	coefficient	was	≥0.994.	Bland-	Altman	plots	
demonstrate constant bias for the four assays and consistency in re-
sults for each site (Figures S9-S12).
3.5 | Reference range studies
Based on fresh samples in Sarstedt tubes, reference ranges (2.5th 
to	97.5th	percentiles	[90%	CI];	200	fresh	samples	per	assay)	were:	
fibrinogen = 193 (167- 202) to  412 (368- 432) mg/dL (Clauss assay), 
median = 275 mg/dL; PT- derived fibrinogen = 204 (193- 212) to 
 412 (360- 466) mg/dL, median = 267 mg/dL; thrombin time = 16.1 
(15.9- 16.4) to  19.7 (19.5- 21.5) seconds, median = 17.8 seconds. In 
TABLE  3 Method	comparison	between	cobas t 711 and cobas t 511 analysers
Assay Evaluation Acceptance criteria
Freiburg Sheffield Sheffield
Lot 1 Lot 2 Lot 3
Fibrinogen (mg/dL) n 140 153
Slope (Passing–Bablok) 1.00 ± 0.10 1.000 0.985
Intercept ≤25.0	mg/dL 4.000 2.524
Pearson’s r ≥0.900 0.999 0.998
Relative % bias at 200 mg/dL NA 2.00 −0.282
PT- derived fibrinogen (mg/dL) n 141 131
Slope (Passing–Bablok) 1.00 ± 0.10 1.004 1.000
Intercept NA 0.823 −2.00
Pearson’s r ≥0.900 0.999 0.951
Bias at 200 mg/dL ±20 mg/dL at 200 mg/dL 1.685 −2.00
Thrombin time (s) n 141 126
Slope (Passing–Bablok) 1.00 ± 0.10 0.919 0.941
Intercept NA 1.424 0.976
Pearson’s r ≥0.900 0.994 0.991
Relative % bias at 17.8 s NA −0.106 −0.397
D- dimer (μg FEU/mL) n 233 192
Slope (Passing–Bablok) 1.000 ± 0.075 1.000 1.004
Intercept ≤±0.10	μg FEU/mL −0.009 0.007
Pearson’s r ≥0.975 1.000 1.000
Relative % bias at 0.5 μg FEU/mL NA −1.8 1.84
FEU,	fibrinogen	equivalent	units;	NA,	not	applicable;	PT,	prothrombin.
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the D- dimer assay reference range test, 70 of 200 samples were 
measurable on the cobas t 711 instrument; the rest fell below the 
limit	of	quantification	(LOQ)	and	were	reported	as	<0.200	μg FEU/
mL;	the	reference	range	(90%	CI)	was	<0.200	(0.200-	1.22)	to		0.58	
(0.200- 1.22) μg FEU/mL.
Comparable reference ranges (2.5th to  97.5th percentiles [90% 
CI])	 were	 obtained	 using	 frozen	 samples	 prepared	 from	 Sarstedt	
tubes: fibrinogen (191 samples) = 188 (176- 203) to  397 (371- 
423) mg/dL, median = 261 mg/dL; PT- derived fibrinogen (200 sam-
ples) = 201 (188- 208) to  408 (358- 463) mg/dL, median = 266 mg/
dL; thrombin time (199 samples) = 15.9 (15.5- 16.0) to  19.3 (19.0- 
19.6) seconds, median = 17.4 seconds. During evaluation of the 
D- dimer assay, 75 of 200 samples were evaluable on cobas t 711, 
while the rest fell below the LOQ; the reference range (90% CI) was 
<0.200	(0.200-	1.21)	to		0.57	(0.200-	1.21)	μg FEU/mL.
Similar	 reference	 ranges	 (2.5th	 to	 	97.5th	 percentiles	 [90%	CI])	
were also obtained using frozen samples stored in Becton- Dickinson 
tubes: fibrinogen (198 samples) = 190 (160- 198) to  407 (380- 
444) mg/dL, median = 276 mg/dL; PT- derived fibrinogen (198 sam-
ples) = 214 (186- 226) to  427 (407- 453) mg/dL, median = 285 mg/
dL; thrombin time (197 samples) = 14.9 (13.5- 15.5) to  19.7 (19.3- 
21.9) seconds, median = 17.3 seconds. During evaluation of the D- 
dimer assay, 71 of 200 samples were evaluable on cobas t 711; the 
rest	fell	below	the	LOQ.	The	reference	range	(90%	CI)	was	<0.200	
(0.200- 2.50) to 0.67 (0.200- 2.50) μg FEU/mL.
4  | DISCUSSION
Each	of	the	four	coagulation	assays	tested	demonstrated	excellent	
analytical performance on both the cobas t 711 and cobas t 511 ana-
lysers.	Overall,	the	CVs	for	all	four	assays	were	≤4.1%	for	within-	run	
precision	and	≤8.6%	for	total	reproducibility;	lot-	to-	lot	comparisons	
with each assay showed a high level of consistency across all sites. 
The fibrinogen, PT- derived fibrinogen, and D- dimer assays per-
formed on the cobas t 711 analyser showed good agreement with 
the commercially available assays/platforms used as comparator 
methods, which have previously demonstrated acceptable perfor-
mance.33,34 Each assay produced high correlation coefficients at all 
sites (fibrinogen, r = 0.990- 0.996; PT- derived fibrinogen, r = 0.938- 
0.943; D- dimer, r = 0.999- 1.000). Thrombin time showed less close 
agreement (r = 0.658- 0.755), but the results were still within accept-
able limits. Thrombin time is an uncalibrated test used to check for 
anticoagulants or clotting abnormalities. Results are reported in sec-
onds, and reagents differ between suppliers, so as a result thrombin 
time tests from different manufacturers are generally less compa-
rable than other tests. Heparin sensitivity of the thrombin time rea-
gents also differs if heparinized samples are used.
Importantly, equivalency was demonstrated between the 
cobas t 711 and cobas t 511 analysers. Both analysers are built from 
functionally identical components and process assays using the 
same reagents and disposables. The main difference between the 
TABLE  4 Lot- to- lot comparison on the cobas t 711 analyser
Assay Evaluation Acceptance criteria
Freiburg Sheffield Debrecen
Lot 2 vs 1 Lot 3 vs 2 Lot 1 vs 3
Fibrinogen (mg/dL) n 140 155 130
Slope (Passing–Bablok) 1.00 ± 0.10 0.993 1.000 0.973
Intercept ≤±20.0	mg/dL 1.651 1.000 3.627
Pearson’s r ≥0.975 0.999 0.999 0.998
Relative % bias at 200 mg/dL NA 0.106 0.500 −0.914
PT- derived fibrinogen (mg/dL) n 144 132 124
Slope (Passing–Bablok) 1.00 ± 0.10 0.962 1.01 1.025
Intercept NA 9.20 −2.79 −4.51
Pearson’s r ≥0.900 0.999 0.998 0.999
Bias at 200 mg/dL ±20 mg/dL at 200 mg/dL 1.55 −0.789 0.529
Thrombin time (s) n 141 126 122
Slope (Passing–Bablok) 1.00 ± 0.10 1.055 0.970 0.991
Intercept NA −1.023 0.386 0.264
Pearson’s r NA 0.997 0.994 0.995
Relative % bias at 17.8 s NA −0.277 −0.860 0.559
D- dimer (μg FEU/mL) n 235 191 133
Slope (Passing–Bablok) 1.000 ± 0.100 0.978 1.029 0.983
Intercept ≤0.1	μg FEU/mL 0.012 −0.022 0.001
Pearson’s r ≥0.975 1.000 1.000 0.999
Relative % bias at 0.5 μg FEU/mL NA 0.246 −1.61 −1.59
FEU,	fibrinogen	equivalent	units;	NA,	not	applicable;	PT,	prothrombin	time.
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two systems is in terms of throughput: the high- throughput cobas t 
711 can process 390 tests/h, and the medium- throughput cobas t 
511 can process 195 tests/h. The cobas t coagulation analysers offer 
innovative features, including high processing power and increased 
walkaway time for mid- to high- volume coagulation laboratories. 
Connectivity, automated reagent reconstitution, and optimized re-
agent and sample management also provide laboratories with im-
proved workflow and operating efficiency.
These four new coagulation assays could provide core laborato-
ries with accurate and reliable tests for the screening, diagnosis and 
assessment of a range of coagulopathies in routine clinical practice. 
The fibrinogen assay using the Clauss method is intended as an aid in 
the detection of hypo- and hyperfibrinogenaemia, dysfibrinogenae-
mia and afibrinogenaemia.35,36 The PT- derived fibrinogen assay is an 
alternative method for measuring fibrinogen, but may be less reliable 
than the Clauss method.36 Thrombin time provides a measure of the 
time taken for a clot to form in plasma to which thrombin has been 
added, and can be used as part of an investigation into potential 
bleeding disorders, and/or to detect the presence of drugs that pre-
vent conversion of fibrinogen to fibrin.37 While the D- dimer assay is 
used	as	an	aid	in	the	exclusion	of	DVT/PE,	it	is	intended	to	provide	
a fast and cost- effective test for triaging patients that present with 
signs and symptoms suggestive of venous thromboembolism.38
This study was designed to avoid biases in the evaluation of an-
alytical performance by obtaining samples from various sources, 
including different collection sites and commercial vendors, and 
by	 conducting	 experiments	 at	 four	 core	 laboratories	 in	 different	
European countries. Furthermore, method comparisons were per-
formed	 with	 existing	 commercially	 available	 assays	 and	 in	 accor-
dance	with	CLSI	EP09-	A3	guidelines.32	A	full	range	of	abnormalities	
were included in the test samples so that the methods were evalu-
ated at all relevant levels of analyte. This study was primarily aimed 
at evaluating analytical performance of the four assays and did not 
assess the clinical performance of the assays.
In	 conclusion,	 this	multicentre	 study	demonstrates	 the	 excel-
lent analytical performance of four new coagulation assays on the 
novel cobas t 711 and cobas t 511 analysers. Each coagulation assay 
showed good or acceptable agreement with other commercially 
available assays, and the improved technologies used offer core 
laboratories	a	number	of	advantages	over	existing	methods	for	the	
assessment of a range of coagulopathies in routine clinical practice.
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